Grants and Contributions

• This Priority Announcement will fund pediatric cancer research that can lead to better outcomes and healthier lives for pediatric cancer patients and their families. The aim is to support promising research projects with the greatest potential for advancing knowledge and improving outcomes.
• Projects must directly and primarily focus on pediatric cancer and pediatric populations (children, adolescents and young adults living with cancer and their families).

• Incorporating sex and gender into health research makes for better science that is more rigorous and more applicable to the needs of everybody. The CIHR Institute of Gender and Health (CIHR-IGH) will provide bridge funding for applications that are relevant to its mandate:
o CIHR-IGH mandate is to foster research excellence regarding the influence of sex and gender on health and to apply these findings to identify and address pressing health challenges facing men, women, girls, boys and gender-diverse people.
• These one (1) year operating grants afford Principal Investigators an opportunity to resubmit their research proposal without the loss of momentum, staff, or trainees.

The specific objective of this funding opportunity is to:

• Create new knowledge through the analysis of existing cohorts, data platforms and/or administrative datasets specific to reproductive, maternal, child, and/or youth health, and in turn improve health outcomes and inform population and public health decision making.

• The CIHR Antimicrobial Resistance (AMR) Research Initiative, under the co-leadership of CIHR's Institute of Infection and Immunity (III) and CIHR's Institute of Population and Public Health (IPPH) supports the development of broader, more cohesive engagement and actions, methods and tools to combat AMR and improve antimicrobial use.
• The CIHR AMR Research Initiative will fund applications that are determined to be relevant to the scope of the Initiative.
• In alignment with CIHR’s commitment to equity, diversity and inclusion (EDI) in the research system, the RI champions EDI as a means to support excellence in research, training and knowledge mobilization. Therefore, we encourage people from diverse backgrounds, including groups underrepresented in science such as women and racial and ethnic minorities, to apply.

• The CIHR Antimicrobial Resistance (AMR) Research Initiative, under the co-leadership of CIHR's Institute of Infection and Immunity (III) and CIHR's Institute of Population and Public Health (IPPH) supports the development of broader, more cohesive engagement and actions, methods and tools to combat AMR and improve antimicrobial use.
• The CIHR AMR Research Initiative will fund applications that are determined to be relevant to the scope of the Initiative.
• In alignment with CIHR’s commitment to equity, diversity and inclusion (EDI) in the research system, the RI champions EDI as a means to support excellence in research, training and knowledge mobilization. Therefore, we encourage people from diverse backgrounds, including groups underrepresented in science such as women and racial and ethnic minorities, to apply.

• The CIHR Institute of Cancer Research (CIHR-ICR) has a mandate to support research that reduces the burden of cancer on individuals and families through prevention strategies, screening, diagnosis, effective treatments, psycho-social support systems, and palliation.
• This priority announcement is designed to support research that reduces the burden of breast cancer on individuals and families through prevention strategies, screening, diagnosis, effective treatment, psycho-social support systems, and palliation.
• This priority announcement will fund research in the following research area:
o Breast Cancer Research

• The CIHR Institute of Cancer Research (CIHR-ICR) has a mandate to support research that reduces the burden of cancer on individuals and families through prevention strategies, screening, diagnosis, effective treatments, psycho-social support systems, and palliation.
• This priority announcement is designed to support research that reduces the burden of breast cancer on individuals and families through prevention strategies, screening, diagnosis, effective treatment, psycho-social support systems, and palliation.
• This priority announcement will fund research in the following research area:
o Breast Cancer Research

• The CIHR Institute of Cancer Research (CIHR-ICR) has a mandate to support research that reduces the burden of cancer on individuals and families through prevention strategies, screening, diagnosis, effective treatments, psycho-social support systems, and palliation.
• This priority announcement is designed to support research that reduces the burden of breast cancer on individuals and families through prevention strategies, screening, diagnosis, effective treatment, psycho-social support systems, and palliation.
• This priority announcement will fund research in the following research area:
o Breast Cancer Research

• The CIHR Institute of Cancer (CIHR-ICR) will provide funding for applications that are determined to be relevant to its mandate:
o The Institute of Cancer Research (ICR) supports research that reduces the burden of cancer on individuals and families through prevention strategies, screening, diagnosis, effective treatments, psycho-social support systems, and palliation

Bridge funding can be used at the NPAs discretion to catalyze work on their proposed project in the manner they feel best moves forward their research program, for example, collection of pilot data, demonstration of feasibility, or work to address peer review comments.

The objective of this funding opportunity is to catalyze and support research efforts of Canadian researchers to use the available CLSA data in order to better understand how (individually and in combination) the biological, medical, psychological, social, lifestyle and/or economic aspects of people’s lives have an impact in both maintaining health and in the development of disease and disability as people age.